Stroke prevention: Which drugs to use and when?

Journal of Neurology

Volumn 246, Issue 9, 1999, Pages 753-757

  Koudstaal, Peter J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulation; Aspirin; Atrial fibrillation; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INDOBUFEN; WARFARIN;

BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; SHORT SURVEY; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTICOAGULANTS; CEREBROVASCULAR ACCIDENT; HUMANS;

EID: 0032833789     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050450     Document Type: Short Survey

References (26)

1. Algra A, van Gijn J (1996) Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 60:197-199
2. American-Canadian Co-operative Study Group (1983) Persantin aspirin trial in cerebral ischemia. II. Endpoint results. Stroke 16:406-415
3. Antiplatelet Trialists' Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 296:320 331
4. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106
5. Atrial Fibrillation Investigators (1997) The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med 157:1237-1240
6. Bousser MG, Eschwege E. Haguenau M. et al (1983) "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 14:5-14
7. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
8. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13
9. Dutch TIA Study Group (1991) A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325:1261-1266
10. Enserink M (1996) Fraud and ethics charges hit stroke drug trial. Science 274:2004-2005
11. EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasly. N Engl J Med 330:956-961
12. EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696
13. European Atrial Fibrillation Trial Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262
14. European Atrial Fibrillation Trial Study Group (1995) Optimal intensity of anticoagulant treatment in nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333:5-10
15. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R (1982) Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires. Résultats d'un essai thérapeutique controlé de 3 ans. Rev Neurol (Paris) 138:367-385
16. Hylek EM, Skates SJ, Sheehan MA. Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540-546
17. International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST); a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 349:1569-1581
18. Kaye J (1990) A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Boehringer Ingelheim internal report. Bracknell
19. Koudstaal PJ (1994.) Primary and secondary prevention of stroke in patients with nonrheumatic atrial fibrillation. Eur Neurol 34:61-63
20. Kronmal RA, Hart RG, Manolio TA, Talbert RL, Beauchamp NJ, Newman A, for the CHS Collaborative Research Group (1998) Aspirin use and incident stroke in the cardiovascular health study. Stroke 29:887-894
21. Masuhr F, Busch M, Einhäupl KM (1998) Differences in medical and surgical therapy for stroke prevention between leading experts in North-America and western Europe. Stroke 29: 339-345
22. Medical Research Council's General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anti-coagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic disease in men at increased risk. Lancet 351:233-241
23. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, et al (1997) Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 28:1015-1021
24. Stroke Prevention in Atrial Fibrillation Investigators (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348:633-638
25. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group (1997) A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42:857-865
26. Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76:12-16